Drug Information

Drug General Information
Drug ID
D06XGC
Former ID
DIB002553
Drug Name
BMS-986202
Synonyms
AM-095; AM-152; AM-152); AM-966; LPA1 antagonists (fibrotic disease), Amira; Lysophosphatidic acid antagonists (fibrotic disease), Amira
Drug Type
Small molecular drug
Indication Idiopathic pulmonary fibrosis [ICD9: 516.3; ICD10:J84.1] Preclinical [542017], [548922]
Company
Bristol-myers squibb; Amira Pharmaceuticals Inc
Structure
Download
2D MOL

3D MOL
Formula
C27H23ClN2O5
InChI
InChI=1S/C27H23ClN2O5/c1-16-25(29-27(33)34-17(2)22-5-3-4-6-23(22)28)26(35-30-16)21-13-11-20(12-14-21)19-9-7-18(8-10-19)15-24(31)32/h3-14,17H,15H2,1-2H3,(H,29,33)(H,31,32)/t17-/m1/s1
InChIKey
WWQTWEWAPUCDDZ-QGZVFWFLSA-N
PubChem Compound ID
46240292
PubChem Substance ID
96102208, 120492571, 135649931, 163620852, 163643256, 163686179, 184816402, 198961982, 219813610, 223624755, 223697971, 228414817, 245138393, 252474509
Target and Pathway
Target(s) Lysophosphatidic acid receptor Edg-2 Target Info Antagonist [531303]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
PI3K-Akt signaling pathway
Gap junction
Pathways in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database LPA receptor mediated events
Reactome G alpha (q) signalling events
G alpha (i) signalling events
Lysosphingolipid and LPA receptors
WikiPathways Myometrial Relaxation and Contraction Pathways
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 542017(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6988).
Ref 548922Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030351)
Ref 531303Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.